• HOME
  • Universe A-Z
  • PSYCH STOCK NEWS
  • PSYCH NEWS
  • RESEARCH
  • TESTIMONIALS
  • CLINICAL TRIALS
  • CONFERENCES
  • 2024 PSYCHEDELIC INVESTOR CONFERENCE
Search
Psychedelic Stock Review

CLIENT

  • 2023 Watch List
  • 2024 WATCH LIST
  • ALCOHOL
  • CHARITY
  • CLIENT
  • CLINICAL TRIALS
  • CLINICS
  • CONFERENCES
  • DECK
  • INTERVIEW
  • INVESTORS
  • IPO
  • LARGE CAP PSYCH
  • NEO
  • PSYCH FUND | ETF
  • PSYCH NEWS
  • PSYCH STOCK NEWS
  • Psychedelic Investor Guide
  • Psychedelic Investor TV
  • RESEARCH
  • SIDE STORIES
  • STUFF
  • SUBSCRIBE
  • TESTIMONIALS
  • UNIVERSE
  • VETS
  • VIDEOS

    Silo Pharma (SILO) Takes Aim at $3.1 Billion Fibromyalgia Market.

    Editor | Curator - January 20, 2024

    Psycheceutical’s (BWVI) Topical Ketamine: A Game-Changer for PTSD?

    Editor | Curator - January 4, 2024

    Psycheceutial Biosciences (BWVI) Listed on WeFunder!

    Editor | Curator - November 1, 2023

    Zappy Zapolin Hopes To Put Ibogaine Front And Center For Addiction

    October 9, 2023

    Shark Tank’s Kevin Harrington Invests In Psychedelics Company Psycheceutical (BWVI). Forbes

    May 15, 2023

    Adding Psycheceutical Bioscience (BWVI) $0.14 to Watch List. (Ketamine.)

    May 15, 2023

    Silo Pharma (SILO) Issues Letter to Shareholders

    December 2, 2022
    KetaDSH

    Ehave, Inc. Announces its KetaDASH Mobile Unit Delivered to Miami Beach.

    June 22, 2022
    ehave, psychedelic stock review

    Ketamine Testimonials On Local Nashville and Miami News. Lamar Odom on...

    October 16, 2021

    Ehave (EHVVF) To Conduct Ketamine Clinical Trial In Miami, Florida

    October 13, 2021

    Psychedelic Stock Review Initiates Coverage on Ehave Inc.

    October 2, 2021
    ehave, psychedelic investor guide

    Ehave (EHVVF) Announces Inclusion in the 2021 Psychedelic Investor Guide

    September 27, 2021
    Ehave, EHVVF

    Report: Ehave Inc (EHVVF) Our Favorite Psychedelic Company

    September 24, 2021
    12Page 1 of 2
    ABOUT US
    FOLLOW US
    • About – Contact
    • Institutional Investors
    • Analysts
    • Side Stories
    • Disclaimer
    ©